“we’re trending toward delivering more than $100 million of annualized purchasing improvement across all of our generics to the PBM and payor customers under CVS CostVantage contracts, and as we continue to improve cost of goods, we pass that through CostVantage to our customers.”

In context

“rics, and this allows us to ensure more stable pharmacy margins and a more durable process as you think about what we do inside the pharmacy supply chain, which is essentially serving the patients at the counter for a more predictable margin for every script that we dispense. Lastly, it creates the path for transparency for PBMs to provide that transparency in their drug pricing as well. In our conversations with payors, I’m excited to say that we got this across the finish line in 100% of our commercial market. Your question as it relates to Medicare and Medicaid, we’re actually working for 1/1/26 to move the rest of our book onto a CostVantage-like model. Our initial results from CostVantage and the industry leading cost of goods that we have, PBMs and payors will benefit from this, and we’re trending toward delivering more than $100 million of annualized purchasing improvement across all of our generics to the PBM and payor customers under CVS CostVantage contracts, and as we continue to improve cost of goods, we pass that through CostVantage to our customers. As we continue to move forward, we’re excited about building this with our payors to create more clinical models and clinical solutions at the counter, where we can leverage the 30,000-plus pharmacists we have serving patients day-in and day-out. Operator: Thank you. We have our final question on the line from Elizabeth Anderson with Evercore. Please go ahead. Elizabeth Anderson: Hi guys, good morning. Thanks so much for the question. Thanks for all the color on the 2025 outlook in particular. I know you said you were looking at four points of Medicaid improvement year-over-year in terms of the pricing, and that you had 40% of it was sort of caught up. Can you talk about how that catches up over the course of 2025? Should we think of that as broadly ratable, or are there any other kind of”